Status:
COMPLETED
A Study of LY3871801 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to compare the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it, when given as crystalline freebase tablet (test) a...
Eligibility Criteria
Inclusion
- Participants who are overtly healthy as determined by medical evaluation including medical history and physical examination.
- Have body weight ≥ 45 kilograms (kg) and body mass index (BMI) within the range 18.5 to 40.0 kilograms per meter squared (kg/m²)
- Participants not of childbearing potential
Exclusion
- Have known allergies to LY3871801, related compounds or any components of the formulation, or history of significant atopy.
- Have an abnormal blood pressure and/or pulse rate, deemed to be clinically significant by the investigator
- Have used or intend to use prescription or nonprescription medication (including dietary supplements, vitamins, herbal supplements, and/or alternative medicines) within 7 days prior to dosing
- History of drug or alcohol abuse in the past 2 years and/or regularly use known drugs of abuse
- Are unwilling to stop alcohol consumption 24 hours prior to admission and while resident at the clinical research unit (CRU).
- Smoke more than 10 cigarettes per day (or the equivalent, including electronic cigarettes) or are unable to abide by the CRU smoking restrictions.
Key Trial Info
Start Date :
February 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 11 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05222399
Start Date
February 4 2022
End Date
March 11 2022
Last Update
March 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lilly Centre for Clinical Pharmacology
Singapore, Singapore, 138623